NEW YORK (GenomeWeb) – HTG Molecular Diagnostics and Qiagen Manchester Ltd., a wholly owned subsidiary of Qiagen, said today that they have inked a master assay development, commercialization, and manufacturing agreement.
The agreement creates a framework for the companies to combine their technological and commercial strengths to offer pharmaceutical companies a complete next-generation sequencing-based solution for the development and commercialization of companion diagnostic tests, with a focus on oncology.
As part of the agreement, Qiagen North American Holdings, another Qiagen subsidiary, has made a minority investment of an undisclosed amount in HTG.
"Our objective is to develop a complete NGS solution from biomarker discovery to commercialized companion diagnostics and we believe this agreement accelerates both companies' efforts. We are excited to offer this solution to customers," HTG President and CEO TJ Johnson said in a statement.
"HTG's extraction-free technology can add attractive capabilities to Qiagen's NGS-based sample-to-insight solutions for applications in pathology where sample often is limited," Kai te Kaat, vice president and head of franchise oncology for Qiagen's molecular diagnostics business area, added in a statement.